Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers.
Loading...
Embargo End Date
ICR Authors
Authors
Loi, P
Schade, AE
Rodriguez, CL
Krishnan, A
Perurena, N
Nguyen, VTM
Xu, Y
Watanabe, M
Davis, RA
Gardner, A
Pilla, NF
Mattioli, K
Popow, O
Gunduz, N
Lannagan, TRM
Fitzgerald, S
Sicinska, ET
Lin, J-R
Tan, W
Brais, LK
Haigis, KM
Giannakis, M
Ng, K
Santagata, S
Helin, K
Sansom, OJ
Cichowski, K
Schade, AE
Rodriguez, CL
Krishnan, A
Perurena, N
Nguyen, VTM
Xu, Y
Watanabe, M
Davis, RA
Gardner, A
Pilla, NF
Mattioli, K
Popow, O
Gunduz, N
Lannagan, TRM
Fitzgerald, S
Sicinska, ET
Lin, J-R
Tan, W
Brais, LK
Haigis, KM
Giannakis, M
Ng, K
Santagata, S
Helin, K
Sansom, OJ
Cichowski, K
Document Type
Journal Article
Date
2024-12-02
Date Accepted
2024-08-07
Abstract
Combined EZH2 and RAS pathway inhibitors kill KRAS-mutant colorectal cancer cells and promote durable tumor regression in vivo. These agents function by cooperatively suppressing the WNT pathway, driving differentiation, and epigenetically reprogramming cells to permit the induction of apoptotic signals, which then kill these more differentiated tumor cells.
Citation
Cancer Discovery, 2024, pp. OF1 - OF20
Source Title
Cancer Discovery
Publisher
AMER ASSOC CANCER RESEARCH
ISSN
2159-8274
eISSN
2159-8290
Collections
Research Team
CEO Office